Annual Working Capital
$249.64 M
-$49.40 M-16.52%
December 31, 2023
Summary
- As of February 7, 2025, RVNC annual working capital is $249.64 million, with the most recent change of -$49.40 million (-16.52%) on December 31, 2023.
- During the last 3 years, RVNC annual working capital has fallen by -$139.40 million (-35.83%).
- RVNC annual working capital is now -35.83% below its all-time high of $389.04 million, reached on December 31, 2020.
Performance
RVNC Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
$249.64 M
-$6.90 M-2.69%
September 30, 2024
Summary
- As of February 7, 2025, RVNC quarterly working capital is $249.64 million, with the most recent change of -$6.90 million (-2.69%) on September 30, 2024.
- Over the past year, RVNC quarterly working capital has dropped by -$56.72 million (-18.52%).
- RVNC quarterly working capital is now -47.64% below its all-time high of $476.81 million, reached on March 31, 2020.
Performance
RVNC Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
RVNC Working Capital Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -16.5% | -18.5% |
| 3 y3 years | -35.8% | +9.5% |
| 5 y5 years | +41.9% | +33.9% |
RVNC Working Capital Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -16.5% | +39.6% | -26.8% | +39.6% |
| 5 y | 5-year | -35.8% | +39.6% | -47.6% | +39.6% |
| alltime | all time | -35.8% | +321.8% | -47.6% | +321.8% |
Revance Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $249.64 M(-2.7%) |
| Jun 2024 | - | $256.54 M(-14.7%) |
| Mar 2024 | - | $300.78 M(+20.5%) |
| Dec 2023 | $249.64 M(-16.5%) | $249.64 M(-18.5%) |
| Sep 2023 | - | $306.36 M(+0.5%) |
| Jun 2023 | - | $304.87 M(+24.4%) |
| Mar 2023 | - | $245.04 M(-18.1%) |
| Dec 2022 | $299.05 M(+67.2%) | $299.05 M(-12.3%) |
| Sep 2022 | - | $340.86 M(+85.5%) |
| Jun 2022 | - | $183.72 M(-14.3%) |
| Mar 2022 | - | $214.26 M(+19.8%) |
| Dec 2021 | $178.83 M(-54.0%) | $178.83 M(-21.6%) |
| Sep 2021 | - | $228.01 M(-23.1%) |
| Jun 2021 | - | $296.36 M(-16.7%) |
| Mar 2021 | - | $355.59 M(-8.6%) |
| Dec 2020 | $389.04 M(+52.2%) | $389.04 M(+0.7%) |
| Sep 2020 | - | $386.45 M(-15.0%) |
| Jun 2020 | - | $454.78 M(-4.6%) |
| Mar 2020 | - | $476.81 M(+86.5%) |
| Dec 2019 | $255.62 M(+45.3%) | $255.62 M(+37.1%) |
| Sep 2019 | - | $186.41 M(-9.2%) |
| Jun 2019 | - | $205.21 M(-15.6%) |
| Mar 2019 | - | $243.05 M(+38.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $175.95 M(-33.4%) | $175.95 M(-4.4%) |
| Sep 2018 | - | $184.08 M(-14.2%) |
| Jun 2018 | - | $214.56 M(-14.3%) |
| Mar 2018 | - | $250.42 M(-5.3%) |
| Dec 2017 | $264.31 M(+52.7%) | $264.31 M(+96.1%) |
| Sep 2017 | - | $134.79 M(-11.5%) |
| Jun 2017 | - | $152.38 M(-12.1%) |
| Mar 2017 | - | $173.41 M(+0.2%) |
| Dec 2016 | $173.05 M(-28.5%) | $173.05 M(-9.5%) |
| Sep 2016 | - | $191.16 M(-7.5%) |
| Jun 2016 | - | $206.64 M(-8.6%) |
| Mar 2016 | - | $226.00 M(-6.6%) |
| Dec 2015 | $241.93 M(+48.9%) | $241.93 M(+83.6%) |
| Sep 2015 | - | $131.76 M(+3.7%) |
| Jun 2015 | - | $127.10 M(-14.8%) |
| Mar 2015 | - | $149.26 M(-8.1%) |
| Dec 2014 | $162.50 M(-480.1%) | $162.50 M(-7.8%) |
| Sep 2014 | - | $176.16 M(-6.2%) |
| Jun 2014 | - | $187.79 M(+173.9%) |
| Mar 2014 | - | $68.56 M(-260.4%) |
| Dec 2013 | -$42.75 M(-62.0%) | -$42.75 M(+49.2%) |
| Sep 2013 | - | -$28.64 M(-74.5%) |
| Dec 2012 | -$112.53 M(-629.2%) | -$112.53 M |
| Dec 2011 | $21.26 M | - |
FAQ
- What is Revance Therapeutics annual working capital?
- What is the all time high annual working capital for Revance Therapeutics?
- What is Revance Therapeutics annual working capital year-on-year change?
- What is Revance Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Revance Therapeutics?
- What is Revance Therapeutics quarterly working capital year-on-year change?
What is Revance Therapeutics annual working capital?
The current annual working capital of RVNC is $249.64 M
What is the all time high annual working capital for Revance Therapeutics?
Revance Therapeutics all-time high annual working capital is $389.04 M
What is Revance Therapeutics annual working capital year-on-year change?
Over the past year, RVNC annual working capital has changed by -$49.40 M (-16.52%)
What is Revance Therapeutics quarterly working capital?
The current quarterly working capital of RVNC is $249.64 M
What is the all time high quarterly working capital for Revance Therapeutics?
Revance Therapeutics all-time high quarterly working capital is $476.81 M
What is Revance Therapeutics quarterly working capital year-on-year change?
Over the past year, RVNC quarterly working capital has changed by -$56.72 M (-18.52%)